Target type: biologicalprocess
Any process that stops, prevents or reduces the frequency, rate or extent of entry of bacterium into host cell. [GOC:obol]
Negative regulation of entry of bacterium into host cell is a complex process that involves a coordinated interplay of host cell and bacterial factors. The entry of bacteria into host cells is a critical step in the pathogenesis of many bacterial infections. To successfully invade a host cell, bacteria must overcome various defense mechanisms, including physical barriers, innate immune responses, and cellular signaling pathways. Negative regulation of bacterial entry, therefore, involves mechanisms that impede or block this process. Here are some key aspects of negative regulation:
* **Host Cell Barriers:** The host cell's outer membrane acts as a physical barrier. Tight junctions between epithelial cells and the presence of mucus layers can hinder bacterial adherence and entry.
* **Innate Immune Responses:** The host's innate immune system plays a crucial role in defending against bacterial invasion. Phagocytic cells like macrophages and neutrophils engulf and destroy invading bacteria. These cells recognize specific bacterial components through pattern recognition receptors (PRRs), triggering the release of antimicrobial peptides and cytokines.
* **Cellular Signaling Pathways:** Host cells utilize various signaling pathways to mount a defense against bacteria. These pathways can activate antimicrobial defenses, promote cell survival, and trigger inflammatory responses. For example, the NF-κB pathway is involved in the expression of pro-inflammatory cytokines that attract immune cells to the site of infection.
* **Antimicrobial Peptides:** Host cells produce antimicrobial peptides that directly target and kill bacteria. These peptides can disrupt bacterial membranes, interfere with bacterial protein synthesis, or block bacterial DNA replication.
* **Competition for Nutrients:** Host cells compete with bacteria for essential nutrients. This can limit the growth and proliferation of invading bacteria.
* **Bacterial Virulence Factors:** Certain bacterial factors, such as toxins and enzymes, can contribute to negative regulation of entry. Some toxins disrupt the host cell membrane, preventing bacterial attachment, while enzymes can degrade components of the host cell's extracellular matrix, hindering bacterial invasion.
* **Antibiotic Resistance:** Bacteria can develop resistance to antibiotics, making them more difficult to eliminate. This resistance can be caused by mutations in bacterial genes that encode proteins involved in antibiotic uptake, metabolism, or efflux.
* **Biofilm Formation:** Bacteria can form biofilms, which are complex communities of bacteria encased in a matrix of extracellular polymers. Biofilms can protect bacteria from host immune defenses and antibiotics, making them more resistant to eradication.
The mechanisms involved in negative regulation of bacterial entry are diverse and complex, and they are often influenced by factors such as the specific bacterial species involved, the host cell type, and the environmental conditions. Understanding these mechanisms is crucial for developing effective strategies to prevent and treat bacterial infections.'
"
Protein | Definition | Taxonomy |
---|---|---|
Integrin alpha-V | An integrin alpha-V that is encoded in the genome of human. [PRO:DNx, UniProtKB:P06756] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
1-(3-chlorophenyl)biguanide | 1-(3-chlorophenyl)biguanide: RN given refers to parent cp; a 5-HT3 receptor agonist | biguanides; monochlorobenzenes | |
phenyl biguanide | phenyl biguanide : A member of the class of biguanides that is biguanide in which one of the terminal nitrogen atoms is substituted by a phenyl group. phenyl biguanide: RN given refers to parent cpd | guanidines | central nervous system drug |
4-chlorophenylbiguanide | |||
paclitaxel | Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL). | taxane diterpenoid; tetracyclic diterpenoid | antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent |
tirofiban | tirofiban : A member of the class of piperidines that is L-tyrosine in which a hydrogen attached to the amino group is replaced by a butylsulfonyl group and in which the hydrogen attached to the phenolic hydroxy group is replaced by a 4-(piperidin-4-yl)butyl group. Tirofiban: Tyrosine analog and PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX antagonist that inhibits PLATELET AGGREGATION and is used in the treatment of ACUTE CORONARY SYNDROME. | L-tyrosine derivative; piperidines; sulfonamide | anticoagulant; fibrin modulating drug; platelet glycoprotein-IIb/IIIa receptor antagonist |
25-hydroxycholesterol | 25-hydroxy steroid; oxysterol | human metabolite | |
tetraiodothyroacetic acid | 3,3',5,5'-tetraiodothyroacetic acid : A monocarboxylic acid that is thyroacetic acid carrying four iodo substituents at positions 3, 3', 5 and 5'. tetraiodothyroacetic acid: RN given refers to parent cpd; structure | 2-halophenol; aromatic ether; iodophenol; monocarboxylic acid | apoptosis inducer; human metabolite; thyroid hormone |
arginyl-glycyl-aspartic acid | arginyl-glycyl-aspartic acid: amino acid sequence of basic unit of widespread cellular recognition system | oligopeptide | |
glycyl-arginyl-glycyl-aspartyl-serine | glycyl-arginyl-glycyl-aspartyl-serine: synthetic peptide from fibronectins; inhibits experimental metastasis of murine melanoma cells | ||
glycyl- arginyl-glycyl-aspartyl-seryl-prolyl-lysine | |||
d-arg-gly-asp-trp | arginyl-glycyl-aspartyl-tryptophan: a synthetic RGD-containing peptide | ||
l 738167 | L 738167: structure in first source | ||
sk&f 107260 | SK&F 107260: structure given in first source | ||
cilengitide | Cilengitide: an alphaVbeta3 integrin antagonist that paralyzes cancer cells | oligopeptide | |
l 734217 | L 734217: fibrinogen receptor antagonist; structure given in first source | ||
elarofiban | elarofiban: a GPIIb and GPIIIa receptor antagonist; structure in first source | ||
eptifibatide | homodetic cyclic peptide; macrocycle; organic disulfide | anticoagulant; platelet aggregation inhibitor | |
arginyl-glycyl-aspartyl-phenylalanine | |||
sb 223245 | |||
cyclic(arg-gly-asp-d-phe-val) | |||
mk-0429 | |||
sb 273005 |